Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL), a Delaware corporation, filed this Current Report on Form 8-K on May 9, 2022. The filing primarily serves to announce the Company's financial results for the quarter ended March 31, 2022, via a press release furnished as Exhibit 99.1. The Company is classified as an emerging growth company.
Key Financial Metrics
The provided text is a cover sheet and index for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for the actual figures regarding revenue, profit, cash flow, margins, debt, and liquidity. Consequently, no specific numerical values for these metrics are available in the source text.
Material Changes
The filing does not detail specific material changes in financial performance or operations within the text provided. It indicates that the Company has updated its corporate deck, available on its investor relations website, which may contain comparative data or operational updates.
Guidance, Outlook, and Risks
The text does not include specific guidance, outlook statements, management commentary, or risk factors. It notes that the information in this report, including the referenced press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 9, 2022) for specific Q1 2022 financial results.
- Access the updated corporate deck on the Company's investor website for operational context.
- Verify the Company's status as an emerging growth company and any related accounting election impacts.
- Confirm the trading symbol (DTIL) and exchange (Nasdaq Global Select Market) for current market data.